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Background
Mucosal tissues are the major route of HIV transmis-
sion. Therefore, designing immunization regimes aimed
to induce mucosal immune response is needed. The aim
of this study was to analyze the activity of IL-12 alone
or in combination with the cholera toxin B subunit
(CTB), applied in DNA-prime/MVA-boost intranasal
immunizations.
Methods
Balb/c mice were intranasally immunized with DNA
expressing HIV-1 EnvB plus DNAIL-12 alone or in combi-
nation with CTB (10ug, applied at prime and booster
doses). Groups receiving CTB, complete cholera toxin
(CT) or non-adjuvants (control) were included. All groups
received MVAEnvB as boost dose. Immune responses
were evaluated 14, 30 or 53 days after immunization.
Results
IL-12 plus CTB generated the highest response, showing a
synergistic effect for both adjuvants, measure by IFN-g
and IL-2 ELISPOT, in spleen (7-fold increment), in regio-
nal (cervical) lymph nodes (LN), genital LN (iliac, GLN)
and, more importantly, in genital tract mucosa (GT). At
memory phase, we found that in the IL-12+CTB group
IFN-g and IL-2 secreting cells were two to three-fold
higher in both systemic and mucosal compartments
(GLNs and GT) (p=0.001).
IL-12+CTB improved several quality features of the
response: i) Higher levels of T-cell polyfunctionality in
spleen and GT. ii) % of specific proliferating cells was
increased at 10, 30 and 53 days. iii) Enhanced in vivo
citotoxicity: median 53% vs 16.4% for control group. iv)
Higher T-cell avidity in spleen cells (p=0.01). v) T-cell
responses with a superior breadth: cross-reactivity
against different Env subtypes was superior.
Conclusion
We demonstrated that IL-12 plus CTB generated a coop-
erative adjuvant effect on the cellular immune response
against Env applied in DNA-MVA intranasal immuniza-
tions. The improvement observed was not only in magni-
tude, but also in the breadth and quality of the responses
induced. These results are important due to the need to
develop mucosal vaccine strategies against HIV.
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